Combining Industry and Private Equity Expertise

  • Clarat is a specialist firm managed by Barry Clare to participate in transactions in the healthcare, medical devices, beauty, personal care and well-being sectors. Clarat works with private equity firms and other investors who wish to become involved in these sectors or to increase their exposure to them.

    Clarat is able to share industry expertise and participate in sector and transaction evaluation with independence, integrity and confidentiality. Clarat normally co-invests in attractive transactions and, where appropriate, Barry Clare can take on an executive or non-executive role. Barry has to date been Chairman of four private equity backed acquisitions: the German generic pharmaceutical firm Betapharm (sold to Dr Reddy in March 2006), Lichtwer, an OTC phytopharma firm (sold to Klosterfrau), Selective Beauty (Paris), an international fine fragrance distribution business, and Healthcare Brands International (HBI). HBI was set up by Clarat to turn scientifically proven healthcare products into leading brands and was originally backed by Goldman Sachs, Essex Woodlands Health Ventures, Abingworth, MVM Life Sciences, 3i and Sofinnova. Its major asset Antula Healthcare was sold the Meda AB. The HBI Ltd company vehicle was retained to be used for further healthcare acquisitions. Most recently Clarat has helped Mid Europa Partners with the acquisition of Walmark, a leading CEE company selling OTC and VMS products.

    Clarat's experience in the healthcare sector with early to late stage companies and expertise in structuring transactions and bridging the gap between technology, commercial opportunity and in raising the required finance, has led to the successful completion of complex and challenging transactions.

    Barry Clare spent many years developing and implementing strategy in healthcare, retail consumer products and financial services, as well as the business to business world. This enables Clarat to offer pragmatic, straightforward, high quality insights based on a wealth of experience and a proven track record in completing private equity backed transactions and creating superior returns for stakeholders through strong team leadership in implementation of strategic goals and exit strategy.

    In addition, Clarat helps early stage companies to commercialise new technology in the healthcare sector. Clarat supports innovators with differentiated technology which can make a fundamental improvement to the delivery of healthcare solutions, by creating the right commercial structure, IP protection, funding and go to market strategy. Typically it involves the creation of a new company for each project, with suitable investors and well qualified management.